OPKO Health Inc (OPK)

  • Get an in-depth profile of OPKO Health Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.

Select Exchange

Symbol Exchange Currency
OPK NASDAQ USD Real-time OPK Mexico MXN Delayed OPK Tel Aviv ILS Delayed
601 -6 (-0.90%)
Closed ILS Disclaimer

OPKO Health Inc Company Profile

Industry
Healthcare Providers & Services
Sector
Healthcare
Employees
4196
Equity Type
ORD
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Contact Information
Address
Miami,33137 United States
Phone
305 575 4100
Fax
-
Web
https://www.opko.com
Top Executives
Name
Age
Since
Title
Tahir Ahmed 0 0000 Member of Scientific Advisory Board
Elias Adam Zerhouni 72 2022 President & Vice Chairman
Steven D. Rubin 63 2007 Executive VP of Administration & Director
Roger J. Medel 76 2020 Independent Director
John A. Paganelli 88 2003 Independent Director
Richard C. Pfenniger 68 2008 Lead Independent Director
Thomas Kodadek 0 0000 Member of Scientific Advisory Board
Jane H. Hsiao 76 2007 Vice Chairman & Chief Technical Officer
Gary J. Nabel 69 2022 Chief Innovation Officer & Director
Lin-Tsing Yu 79 2009 Independent Director
Phillip Frost 87 2007 Chairman & CEO

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.